The neuromelanin of human substantia nigra: Structure, synthesis and molecular behaviour

Journal of Neural Transmission, Supplement

Volumn , Issue 65, 2003, Pages 145-155

  Zecca, L ^a,f   Zucca, F A ^a   Costi, P ^a   Tampellini, D ^a   Gatti, A ^a   Gerlach, M ^b   Riederer, P ^b   Fariello, R G ^c   Ito, S ^d   Gallorini, M ^a   Sulzer, D ^e  

^a CNR   (Italy)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Newron Pharmaceuticals   (Italy)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL; IRON; LIPID; MELANIN; METAL; NEUROMELANIN; PESTICIDE; TOXIN; IRON CHELATING AGENT; LIPOFUSCIN; NERVE PROTEIN; NEUROPROTECTIVE AGENT;

AGING; BINDING AFFINITY; BIOSYNTHESIS; CHELATION; CONFERENCE PAPER; CYTOSOL; HUMAN; MOLECULAR DYNAMICS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SUBSTANTIA NIGRA; CHEMISTRY; METABOLISM; NERVE CELL; PATHOLOGY; REVIEW;

AGING; HUMANS; IRON CHELATING AGENTS; LIPOFUSCIN; MELANINS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0141975261     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0643-3_8     Document Type: Conference Paper

References (83)

1. Adams JD, Odunze IN (1991) Biochemical of 1-methyl-4-phenyl-1,2,3,5- tetrahydropyridine toxicity: could oxidative stress be involved in the brain? Biochem Pharmacol 41: 1099-1105
2. Adler A (1942) Melanin pigment in the central nervous system vertebrates. J Comp Neurol 76: 501
3. Aime S, Fasano M, Bergamasco B, Lopiano L, Valente G (1994) Evidence for a glicid-lipid matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. J Neurochem 62: 369-371
4. Barden H (1969) The histochemical relationship of neuromelanin and lipofuscin. J Neuropathol Exp Neurol Baltimore 28: 419-441
5. Barden H (1975) Histochemical relationship and nature of neuromelanin. Aging 1: 79-117
6. Bazelon M, Fenichel GM (1967) Studies on neuromelanin I. A melanin system in the human adult brainstem. Neurology 17: 512-519
7. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455
8. Bogerts B (1981) A brainstem atlas of catecolaminergic neurons in man, using melanin as natural marker. J Comp Neurol 197: 63-80
9. Bridelli MG, Tampellini D, Zecca L (1999) The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. Febs Lett 457: 18-22
10. Carstam R, Brink C, Hindemint-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of substantia nigra. Biochim Biophys Acta 1097: 152-160
11. Cheng J, Moss SC and Eisner M (1994) X-Ray characterization of melanins-II. Pigment Cell Res 7: 263-273
12. Cotzias GC, Papavasidou PS, Van Woert MH, Sakamoto A (1964) Melanogenesis and extrapiramidal disorders. Fed Proc 233: 713-718
13. Cowen D (1986) The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J Neuropathol Exp Neurol 45: 205-221
14. Cozzi B, Tozzi F (1985) A spectroscopy study of the equine brain melanins. Archo Vet It, Milano 36: 34-40
15. Cozzi B, Pellegrini M, Droghi A (1988) Neuromelanin in the substantia nigra of adult horses. Anat Anz Jena 166: 53-61
16. Crippa R, Wang QJ, Eisner M, Moss SC, Zecca L, Zachack P, Gog T (1996) Structure of human neuromelanin by X-Ray diffraction: comparison with synthetics. Pigment Cell Res 5: 72
17. D'Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231: 987-989
18. DeMattei M, Levi AC, Fariello RG (1986) Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci Lett 72: 37-42
19. Dexter DT, Wells FR, Lees AJ, Jenner I, Marsden CD (1989) Increased nigral iron content and alteration in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836
20. Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75: 2583-2589
21. Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J Neuropathol Exp Neurol 24: 398-414
22. Enochs WS, Nilges MJ, Swartz HM (1993) Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J Neurochem 61: 68-79
23. Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM (1994) The roles of neuromelanin binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J Neural Transm [PD-Sect] 7: 83-100
24. Fenichel GM, Bazelon M (1968) Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 18: 817-820
25. Foley JM, Baxter D (1958) On the nature of pigment granules in the cell of the locus coeruleus and substantia nigra. J Neuropathol Exp Neurol 7: 586-598
26. Fornsted B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivates of dopamine, dopa and dopac in brains of eight mammalian species. Neuropharmacology 25: 451-454
27. Galazka-Friedman J, Bauminger ER, Friedman A, Barcikowska M, Hechel D, Nowik I (1996) Iron in parkinsonian and control substantia nigra, a Mossbauer spectroscopy study. Mov Disord 11: 8-16
28. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987-1041
29. Gerlach M, Trautwein AX, Zecca L, Youdim MBH, Riederer P (1995) Mössbauer spectroscopic studies of human neuromelanin isolated from the substantia nigra. J Neurochem 65: 923-926
30. Gibb WRG (1992) Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 581: 283-291
31. Gibb WRG, Fearnley JM, Lees AJ (1990) The anatomy of the human substantia nigra in relation to selective neuronal vulnerability. In: Streifler MB, Korczyn AD, Melamed E and Youdim MBH (eds) Advances in neurology, vol 53. Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York, pp 31-34
32. Good PF, Olanow CW, Perl DP (1992) Neuromelanin containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res 593: 343-346
33. Graham DG (1979) On the origin and significance of neuromelanin. Arch Pathol Lab Med (July) 103: 359-362
34. Haavik J, Almas B, Flatmark T (1997) Generation of reactive oxygen species by tyrosine hydroxilase: a possible contribution to the degeneration of dopaminergic neurons. J Neurochem 68 (1): 328-332
35. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64: 919-924
36. Hirosawa K (1968) Electron microscopic studies on pigment granules in the substantia nigra and locus coeruleus of the Japanese monkey (macaca fuscata yukui). Z Zellforsch 88: 187-203
37. Höck A, Demmel U, Schicha H, Kasperek K, Feinendegen LE (1975) Trace element concentration in human brain. Brain 98: 49-64
38. Hornykiewicz O (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19-22
39. Ikemoto K, Nagatsu I, Ito S, King RA, Nishimura A, Nagatsu T (1998) Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? Neurosci Lett 253: 198-200
40. Jellinger K, Kienzl E, Rumpelmaier G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168-1171
41. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 59: 1080-1089
42. Kropf AJ, Bunker BA, Eisner M, Moss SC, Zecca L, Stroppolo A, Crippa PR (1998) X-ray absorption fine-structure spectroscopy studies of iron sites in synthetic and natural neuromelanin. Biophys J 75: 3135-3142
43. Kubis N, Faucheux BA, Ransmary G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw J-J, Agid Y, Hirsch EC (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123: 366-373
44. Langston JW, Irwin I (1986) MPTP: current concepts and controversies. Clin Neuropharmacol 9: 485-507
45. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to product of meperidine-analog synthesis. Science 219: 979-980
46. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of human years after 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605
47. 14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 93: 1-6
48. Lopiano L, Chiesa M, Digilio G, Giraudo S, Bergamasco B, Torre E, Fasano M (2000) Q-band EPR investigations of neuromelanin in control and Parkinson Disease patients. Biochim Biophys Acta 1500 (3): 306-312
49. Mann DMA, Yates PO (1974) Lipoprotein pigments- their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 97: 489-498
50. Mann DM, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 21: 193-203
51. Markesbery WR, Ehmann WD, Alauddin M, Hossain TI (1984) Brain trace element in aging. Neurobiol Aging 5: 19-28
52. Marsden CD (1961) Pigmentation in the nuculeus substantiae nigrae of mammals. J Anat 95: 1080-1089
53. Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ (1999) Enzyme activity of macrofage migration inhibitory factor toward oxidized catecholamines. J Biol Chem 274: 3268-3271
54. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's Disease. J Neurochem 64: 1645-1654
55. McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal functions. Arch Neurol 34: 33-35
56. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer disease brains. Neurology 38 (8): 1285-1291
57. Moses HL, Ganote CE, Beaver DL, Shuffman SS (1966) Light and electron microscopic studies of pigment in human and rhesus monkey substantia nigra and locus coeruleus. Anat Rec 155: 167-184
58. Muthane UB, Yasha TC, Shankar SK (1998) Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 43: 283-287
59. Odh G, Carstam R, Paulson J, Wittbjer A, Rosengren E, Rosman H (1994) Neuromelanin of the human substantia nigra: a mixed type melanin. J Neurochem 62: 2030-2036
60. Okun MR (1997) The role of peroxidase in neuromelanin synthesis: a review. Physiol Chem Phys and Med NMR 29: 15-22
61. Pakkenberg B, Moller A, Gundersen HJG, Mouritzen DA, Pakkenberg H (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54: 30-35
62. Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63: 247-253
63. Salazar M, Sokoloski TD, Patil PN (1978) Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed Proc 37: 2403-2407
64. Sanchez-Ferrer A, Rodriguez-Lopez JN, Garcia-Canovas F, Garcia-Carmona F (1995) Tyrosinase: a review of its mechanism. Biochim Biophys Acta 1247: 1-11
65. Schrerer HJ (1939) Melanin pigmentation of the substantia nigra in primates. J Comp Neurol 71: 91
66. Shima T, Sarna T, Stroppolo A, Gerbasi R, Swartz HM, Zecca L (1997) Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 23: 110-119
67. Singer TP, Castagnoli N, Ramsay RR, Trevor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,5- tetraydropiridine. J Neurochem 49: 1-8
68. Smythies J (1996) On the function of neuromelanin. Proc Roy Soc Lond B 263: 487-489
69. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in Substantia nigra zone compacta of parkinsonian brain. J Neurochem 56: 978-982
70. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karetekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci 97 (22): 11869-11874
71. Swartz HM, Sarna T, Zecca L (1992) Modulation by neuromelanins of the availability and reactivity of metal ions. Ann Neurol 32: S69-S75
72. Tief K, Schmidt A, Beerman F (1998) New evidence for presence of tyrosinase in substantia nigra, forebrain, and midbrain. Mol Brain Res 53: 307-310
73. Van Woert MH, Ambani LM (1974) Biochemistry of neuromelanin. Adv Neurol 5: 215-223
74. Wakamatsu K, Ito S and Nagatsu T (1991) Cysteinyldopamine is not incorporated into neuromelanin. Neurosci Lett 131: 57-60
75. Xu Y, Stokes AH, Freeman WM, Kumer S, Vogt B, Vrana K (1997) Tyrosinase mRNA is expressed in human substantia nigra. Mol Brain Res 45: 159-162
76. Zareba M, Bober A, Korytowski W, Zecca L, Sarna T (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim Biophys Acta 1271: 343-348
77. Zecca L, Swartz HM (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J Neural Transm [PD-Sect] 5: 203-213
78. Zecca L, Mecacci C, Seraglia R, Parati E (1992) The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1138: 6-10
79. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 62: 1097-1101
80. Zecca L, Shima T, Stroppolo A, Goj C, Battiston GA, Gerbasi R, Sarna T, Swartz HM (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neurosci 73: 407-415
81. Zecca L, Costi P, Mecacci C, Ito S, Terreni T, Sonnino S (2000) The interaction of human substantia nigra neuromelanin with lipids and peptides. J Neurochem 74: 1758-1765
82. Zecca L, Gallorini L, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin in substantia nigra of normal subjects at different ages. Consequences for iron storage and neurodegenerative disorders. J Neurochem 76: 1766-1773
83. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 510: 216-220